Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments

Arrigo F G Cicero, Giuseppe Derosa, Angelo Parini, Cristina Baronio, Claudio Borghi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: to evaluate the main factors associated with long-term persistence in fully paid lipid-lowering treatment. Methods: We selected 628 moderately hypercholesterolemic subjects (M: 307; F: 311, mean age 59±9 years old), to whom we firstly prescribed a statin (N. 397) or different kinds of lipid-lowering nutraceuticals (N. 231). Then, depending on their will, patients took brand statin (N. 194) or generic statins (N. 203). Results: The main determinants of long-term persistence in therapy are female sex (OR 1.21, 95%CI 1.08-1.42), family history of early cardiovascular disease (OR 1.31, 95%CI 1.13-1.49), baseline LDL-C (OR 1.19, 95%CI 1.02-1.33) and treatment with nutraceuticals versus statins (OR 1.29, 95%CI 1.14-1.38). Persistence appears not to be influenced by patient's age, smoking habit, adverse events during treatment, and estimated cardiovascular risk. Conclusion: Among self-paying patients with mild hyperlipidemia, medication persistence is highest among those taking nutraceuticals, followed by brand statins, followed by generic statins.

Original languageEnglish
Pages (from-to)81-83
Number of pages3
JournalAtherosclerosis
Volume235
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Dietary Supplements
Therapeutics
Medication Adherence
Hyperlipidemias
Habits
Cardiovascular Diseases
Smoking

Keywords

  • Nutraceuticals
  • Persistence
  • Reimbursement
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. / Cicero, Arrigo F G; Derosa, Giuseppe; Parini, Angelo; Baronio, Cristina; Borghi, Claudio.

In: Atherosclerosis, Vol. 235, No. 1, 2014, p. 81-83.

Research output: Contribution to journalArticle

Cicero, Arrigo F G ; Derosa, Giuseppe ; Parini, Angelo ; Baronio, Cristina ; Borghi, Claudio. / Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. In: Atherosclerosis. 2014 ; Vol. 235, No. 1. pp. 81-83.
@article{b937f42869604189ab89e05f6623557c,
title = "Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments",
abstract = "Objective: to evaluate the main factors associated with long-term persistence in fully paid lipid-lowering treatment. Methods: We selected 628 moderately hypercholesterolemic subjects (M: 307; F: 311, mean age 59±9 years old), to whom we firstly prescribed a statin (N. 397) or different kinds of lipid-lowering nutraceuticals (N. 231). Then, depending on their will, patients took brand statin (N. 194) or generic statins (N. 203). Results: The main determinants of long-term persistence in therapy are female sex (OR 1.21, 95{\%}CI 1.08-1.42), family history of early cardiovascular disease (OR 1.31, 95{\%}CI 1.13-1.49), baseline LDL-C (OR 1.19, 95{\%}CI 1.02-1.33) and treatment with nutraceuticals versus statins (OR 1.29, 95{\%}CI 1.14-1.38). Persistence appears not to be influenced by patient's age, smoking habit, adverse events during treatment, and estimated cardiovascular risk. Conclusion: Among self-paying patients with mild hyperlipidemia, medication persistence is highest among those taking nutraceuticals, followed by brand statins, followed by generic statins.",
keywords = "Nutraceuticals, Persistence, Reimbursement, Statin",
author = "Cicero, {Arrigo F G} and Giuseppe Derosa and Angelo Parini and Cristina Baronio and Claudio Borghi",
year = "2014",
doi = "10.1016/j.atherosclerosis.2014.04.016",
language = "English",
volume = "235",
pages = "81--83",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments

AU - Cicero, Arrigo F G

AU - Derosa, Giuseppe

AU - Parini, Angelo

AU - Baronio, Cristina

AU - Borghi, Claudio

PY - 2014

Y1 - 2014

N2 - Objective: to evaluate the main factors associated with long-term persistence in fully paid lipid-lowering treatment. Methods: We selected 628 moderately hypercholesterolemic subjects (M: 307; F: 311, mean age 59±9 years old), to whom we firstly prescribed a statin (N. 397) or different kinds of lipid-lowering nutraceuticals (N. 231). Then, depending on their will, patients took brand statin (N. 194) or generic statins (N. 203). Results: The main determinants of long-term persistence in therapy are female sex (OR 1.21, 95%CI 1.08-1.42), family history of early cardiovascular disease (OR 1.31, 95%CI 1.13-1.49), baseline LDL-C (OR 1.19, 95%CI 1.02-1.33) and treatment with nutraceuticals versus statins (OR 1.29, 95%CI 1.14-1.38). Persistence appears not to be influenced by patient's age, smoking habit, adverse events during treatment, and estimated cardiovascular risk. Conclusion: Among self-paying patients with mild hyperlipidemia, medication persistence is highest among those taking nutraceuticals, followed by brand statins, followed by generic statins.

AB - Objective: to evaluate the main factors associated with long-term persistence in fully paid lipid-lowering treatment. Methods: We selected 628 moderately hypercholesterolemic subjects (M: 307; F: 311, mean age 59±9 years old), to whom we firstly prescribed a statin (N. 397) or different kinds of lipid-lowering nutraceuticals (N. 231). Then, depending on their will, patients took brand statin (N. 194) or generic statins (N. 203). Results: The main determinants of long-term persistence in therapy are female sex (OR 1.21, 95%CI 1.08-1.42), family history of early cardiovascular disease (OR 1.31, 95%CI 1.13-1.49), baseline LDL-C (OR 1.19, 95%CI 1.02-1.33) and treatment with nutraceuticals versus statins (OR 1.29, 95%CI 1.14-1.38). Persistence appears not to be influenced by patient's age, smoking habit, adverse events during treatment, and estimated cardiovascular risk. Conclusion: Among self-paying patients with mild hyperlipidemia, medication persistence is highest among those taking nutraceuticals, followed by brand statins, followed by generic statins.

KW - Nutraceuticals

KW - Persistence

KW - Reimbursement

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84901822153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901822153&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2014.04.016

DO - 10.1016/j.atherosclerosis.2014.04.016

M3 - Article

VL - 235

SP - 81

EP - 83

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -